TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-9.39%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$982M
AUM Growth
+$982M
(+2.2%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
15.44%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
143
New
43
Increased
39
Reduced
6
Closed
15
Top Buys
| 1 |
Dynavax Technologies
DVAX
|
$28.1M |
| 2 |
ANI Pharmaceuticals
ANIP
|
$19.1M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$15.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$14.9M |
| 5 |
CRISPR Therapeutics
CRSP
|
$10.8M |
Top Sells
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$14.5M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$9.44M |
| 4 |
Intellia Therapeutics
NTLA
|
$5.5M |
| 5 |
BLUE
bluebird bio
BLUE
|
$3.2M |
Sector Composition
| 1 | Healthcare | 95.92% |
| 2 | Technology | 1.53% |
| 3 | Real Estate | 0.71% |
| 4 | Communication Services | 0.66% |
| 5 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Merus
MRUS
$5.04B
| $5.92M | 0.6% |
+100,000
| New | +$5.92M |
|
52
Meta Platforms (Facebook)
META
$1.85T
| $5.75M | 0.59% |
11,396
+1,396
| +14% | +$704K |
|
53
Structure Therapeutics
GPCR
$1.14B
| $5.67M | 0.58% |
144,500
+44,500
| +45% | +$1.75M |
|
|
MRNS
54
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $5.62M | 0.57% |
+4,800,000
| New | +$5.62M |
|
55
Cytokinetics
CYTK
$5.98B
| $5.42M | 0.55% |
100,000
| – | – |
|
|
ONC
56
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $5.28M | 0.54% |
37,000
| – | – |
|
57
Design Therapeutics
DSGN
$339M
| $4.96M | 0.51% |
1,480,975
| – | – |
|
58
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.94M | 0.5% |
800,000
| – | – |
|
59
Biohaven
BHVN
$1.71B
| $4.86M | 0.49% |
140,000
| – | – |
|
60
Arvinas
ARVN
$580M
| $4.79M | 0.49% |
180,000
| – | – |
|
61
Alexandria Real Estate Equities
ARE
$13.9B
| $4.68M | 0.48% |
+40,000
| New | +$4.68M |
|
|
OKUR
62
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $4.52M | 0.46% |
2,996,260
-740
| -0% | -$1.12K |
|
63
Liquidia Corp
LQDA
$2.52B
| $4.2M | 0.43% |
350,000
+200,000
| +133% | +$2.4M |
|
64
Lantheus
LNTH
$3.75B
| $4.01M | 0.41% |
50,000
| – | – |
|
65
Iovance Biotherapeutics
IOVA
$800M
| $4.01M | 0.41% |
500,000
| – | – |
|
66
Apogee Therapeutics
APGE
$2.27B
| $3.94M | 0.4% |
100,000
| – | – |
|
67
Enanta Pharmaceuticals
ENTA
$189M
| $3.89M | 0.4% |
300,000
| – | – |
|
68
Seer Inc
SEER
$114M
| $3.86M | 0.39% |
2,300,000
+1,625,875
| +241% | +$2.73M |
|
69
Nkarta
NKTX
$149M
| $3.25M | 0.33% |
550,000
| – | – |
|
70
Bolt Biotherapeutics
BOLT
$9.29M
| $2.86M | 0.29% |
3,812,773
+392,773
| +11% | +$295K |
|
71
Athira Pharma
ATHA
$15.5M
| $2.79M | 0.28% |
1,052,715
+200,000
| +23% | +$530K |
|
72
Genmab
GMAB
$16.7B
| $2.51M | 0.26% |
100,000
| – | – |
|
73
Inhibrx
INBX
$403M
| $2.37M | 0.24% |
+167,500
| New | +$2.37M |
|
74
Fate Therapeutics
FATE
$115M
| $2.3M | 0.23% |
700,000
| – | – |
|
75
Century Therapeutics
IPSC
$40.4M
| $2.3M | 0.23% |
900,000
| – | – |
|